Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment

References

• Curado MP, Voti L, Sortino-Rachou AM. Cancer registration data and quality indicators in low and middle income countries: their interpretation and potential use for the improvement of cancer care. Cancer Caus. Control. 2009;20:751–756. doi:10.1007/s10552-008-9288-5
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA: A. Cancer J. Clin. 2015;65:87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Demaria M, O'Leary MN, Chang J, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017;7:165–176. doi:10.1158/2159-8290.cd-16-0241
   PubMed Web of Science ®Google Scholar
• Chang J, Ren H, Zhao M, et al. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro. Eur. J. Med. Chem. 2017;138:669–688. doi:10.1016/j.ejmech.2017.07.005
   PubMed Web of Science ®Google Scholar
• Kasture VS, Musmade DS, Aher SJ, et al. Tyrosine kinases: promising targets for cancer chemotherapy. Med. Chem. Drug Discov. 2012;2:37–51. doi:10.3390/ijms222111659
   Google Scholar
• Huang M, Shen A, Ding J, et al. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol. Sci. 2014;35:41–50. doi:10.1016/j.tips.2013.11.004
   PubMed Web of Science ®Google Scholar
• Nasser AA, Eissa IH, Oun MR, et al. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFRWT and EGFRT790M. Org. Biomol. Chem. 2020;18:7608–7634. doi:10.1039/d0ob01557a
   PubMed Web of Science ®Google Scholar
• Elshaier YAMM, Shaaban MA, Abd El Hamid MK, et al. Design and synthesis of pyrazolo[3,4-d]pyrimidines: nitric oxide releasing compounds targeting hepatocellular carcinoma. Bioorg. Med. Chem. 2017;25:2956–2970. doi:10.1016/j.bmc.2017.03.002
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu J, Wang A, et al. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC. Eur. J. Med. Chem. 2017;139:674–697. doi:10.1016/j.ejmech.2017.08.035
   PubMed Web of Science ®Google Scholar
• Gaber AA, Bayoumi AH, El-morsy AM, et al. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers. Bioorg. Chem. 2018;80:375–395. doi:10.1016/j.bioorg.2018.06.017
   PubMed Web of Science ®Google Scholar
• Al-Warhi T, Al-Karmalawy AA, Elmaaty AA, et al. Biological evaluation, docking studies, and in silico ADME prediction of some pyrimidine and pyridine derivatives as potential EGFRWT and EGFRT790M inhibitors. J. Enzyme Inhib. Med. Chem. 2023;38:176–191. doi:10.1080/14756366.2022.2135512
   PubMed Web of Science ®Google Scholar
• He J, Zhou Z, Sun X, et al. The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation. Eur. J. Med. Chem. 2021;210:112995–1121005. doi:10.1016/j.ejmech.2020.112995
   PubMed Web of Science ®Google Scholar
• Zheng M, Huo J, Gu X, et al. Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP. J. Med. Chem. 2021;64:7839–7852. doi:10.1021/acs.jmedchem.1c00649
   PubMed Web of Science ®Google Scholar
• Allam HA, Aly EE, Farouk AKBAW, et al. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents. Bioorg. Chem. 2020;98:103726–103738. doi:10.1016/j.bioorg.2020.103726
   PubMed Web of Science ®Google Scholar
• Eissa AAM, Aljamal KFM, Ibrahim HS, et al. Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity. Bioorg. Chem. 2021;116:105318–105327. doi:10.1016/j.bioorg.2021.105318
   PubMed Web of Science ®Google Scholar
• Mohassab AM, Hassan HA, Abdelhamid D, et al. Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases. Bioorg. Chem. 2021;106:104510–104522. doi:10.1016/j.bioorg.2020.104510
   PubMed Web of Science ®Google Scholar
• Wu C-H, Coumar MS, Chu C-Y, et al. Design and synthesis of Tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael Acceptor Group for maximal potency. J. Med. Chem. 2010;53:7316–7326. doi:10.1021/jm100607r
   PubMed Web of Science ®Google Scholar
• Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, Phase III trial. Lancet Oncol. 2019;20:625–635. doi:10.1016/S1470-2045(19)30035-X
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, Phase III trial. The Lancet Oncol. 2019;20:1655–1669. doi:10.1016/S1470-2045(19)30634-5
   PubMed Web of Science ®Google Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J. Clin. Oncol. 2019;38:124–136. doi:10.1200/jco.19.01154
   PubMed Web of Science ®Google Scholar
• Zhong W-Z, Wang Q, Mao W-M, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J. Clin. Oncol. 2021;39:713. doi:10.1200/JCO.20.01820
   PubMed Web of Science ®Google Scholar
• Kim Y, Lee S-H, Ahn JS, et al. Efficacy and safety of Afatinib for EGFR-mutant non-small-cell lung cancer, compared with gefitinib or erlotinib. Off. J. Korean Cancer Assoc. 2019;51:502–509. doi:10.4143/crt.2018.117
   Google Scholar
• Ayati A, Moghimi S, Salarinejad S, et al. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg. Chem. 2020;99:103811–103820. doi:10.1016/j.bioorg.2020.103811
   PubMed Web of Science ®Google Scholar
• Lee AR, Lee S, Shin JY, et al. Biomarker LEPRE1 induces pelitinib-specific drug responsiveness by regulating ABCG2 expression and tumor transition states in human leukemia and lung cancer. Sci. Rep. 2022;12:2928–2940. doi:10.1038/s41598-022-06621-w
   PubMed Web of Science ®Google Scholar
• Yadav P, Shah K. Quinolines, a perpetual, multipurpose scaffold in medicinal chemistry. Bioorg. Chem. 2021;109:104639. doi:10.1016/j.bioorg.2021.104639
   PubMed Web of Science ®Google Scholar
• Goldman J, Bueno AM, Dooms C, et al. Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: findings from the SUMMIT basket trial. Eur. J. Cancer. 2022;174–188:S82. doi:10.1016/S0959-8049(22)01017-6
   Web of Science ®Google Scholar
• Herman KD, Wright CG, Marriott HM, et al. The EGFR/ErbB inhibitor neratinib modifies the neutrophil phosphoproteome and promotes apoptosis and clearance by airway macrophages. Front. Immunol. 2022;13:956991–956999. doi:10.3389/fimmu.2022.956991
   PubMed Web of Science ®Google Scholar
• Zou M, Li J, Jin B, et al. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorg. Chem. 2021;114:105200. doi:10.1016/j.bioorg.2021.105200
   PubMed Web of Science ®Google Scholar
• Kim Y, Ko J, Cui Z, et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol. Cancer Ther. 2012;11:784–791. doi:10.1158/1535-7163.mct-11-0750
   PubMed Web of Science ®Google Scholar
• Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a Phase II trial in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2010;28:3076–3083. doi:10.1200/jco.2009.27.9414
   PubMed Web of Science ®Google Scholar
• Ding S, Gao Z, Hu Z, et al. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors. Eur. J. Med. Chem. 2022;238:114492–114501. doi:10.1016/j.ejmech.2022.114492
   PubMed Web of Science ®Google Scholar
• Ayati A, Moghimi S, Toolabi M, et al. Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy. Eur. J. Med. Chem. 2021;221:113523–113531. doi:10.1016/j.ejmech.2021.113523
   PubMed Web of Science ®Google Scholar
• Hu X, Tang S, Yang F, et al. Design, synthesis, and antitumor activity of olmutinib derivatives containing acrylamide moiety. Molecules 2021;26:3041–3055. doi:10.3390/molecules26103041
   PubMed Web of Science ®Google Scholar
• Elkaeed EB, Yousef RG, Elkady H, et al. New anticancer theobromine derivative targeting EGFRWT and EGFRT790M: design, semi-synthesis, in silico, and in vitro anticancer studies. Molecules 2022;27:5859–5870. doi:10.3390/molecules27185859
   PubMed Web of Science ®Google Scholar
• Mansour MA, AboulMagd AM, Abbas SH, et al. Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small-cell lung cancer resistance: a critical review. RSC Adv. 2023;13:18825–18853. doi:10.1039/D3RA02347H
   PubMed Web of Science ®Google Scholar
• Matada BS, Pattanashettar R, Yernale NG. A comprehensive review on the biological interest of quinoline and its derivatives. Bioorg. Med. Chem. 2021;32:115973–115991. doi:10.1016/j.bmc.2020.115973
   PubMed Web of Science ®Google Scholar
• Ibrahim DA, Abou El Ella DA, El-Motwally AM, et al. Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity. Eur. J. Med. Chem. 2015;102:115–131. doi:10.1016/j.ejmech.2015.07.030
   PubMed Web of Science ®Google Scholar
• Zaraei S-O, Al-Ach NN, Anbar HS, et al. Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity. Eur. J. Med. Chem. 2022;238:114434. doi:10.1016/j.ejmech.2022.114434
   PubMed Web of Science ®Google Scholar
• Othman DI, Selim KB, Magda A-A, et al. Design, synthesis and anticancer evaluation of new substituted thiophene-quinoline derivatives. Bioorg. Med. Chem. 2019;27:115026. doi:10.1016/j.bmc.2019.07.042
   PubMed Web of Science ®Google Scholar
• Tang Z, Peng Y, Liu F. Design and synthesis of novel quinoline derivatives bearing oxadiazole, isoxazoline, triazolothiadiazole, triazolothiadiazine, and piperazine moieties. J. Heterocycl. Chem. 2020;57:2330–2338. doi:10.1002/jhet.3907
   Web of Science ®Google Scholar
• Jin G, Li Z, Xiao F, et al. Optimization of activity localization of quinoline derivatives: design, synthesis, and dual evaluation of biological activity for potential antitumor and antibacterial agents. Bioorg. Chem. 2020;99:103837–103849. doi:10.1016/j.bioorg.2020.103837
   PubMed Web of Science ®Google Scholar
• Jin G, Xiao F, Li Z, et al. Design, synthesis, and dual evaluation of quinoline and quinolinium iodide salt derivatives as potential anticancer and antibacterial agents. ChemMedChem. 2020;15:600–609. doi:10.1002/cmdc.202000002
   PubMed Web of Science ®Google Scholar
• Fu H-G, Li Z-W, Hu X-X, et al. Synthesis and biological evaluation of quinoline derivatives as a novel class of broad-spectrum antibacterial agents. Molecules. 2019;24:548–561. doi:10.3390/molecules24030548
   PubMed Web of Science ®Google Scholar
• Kaur R, Kumar K. Synthetic and medicinal perspective of quinolines as antiviral agents. Eur. J. Med. Chem. 2021;215:113220–113229. doi:10.1016/j.ejmech.2021.113220
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang G, Zhao J, et al. Synthesis and antiviral activity of a series of novel quinoline derivatives as anti-RSV or anti-IAV agents. Eur. J. Med. Chem. 2021;214:113208. doi:10.1016/j.ejmech.2021.113208
   PubMed Web of Science ®Google Scholar
• Ghanim AM, Girgis AS, Kariuki BM, et al. Design and synthesis of ibuprofen-quinoline conjugates as potential anti-inflammatory and analgesic drug candidates. Bioorg. Chem. 2022;119:105557–105569. doi:10.1016/j.bioorg.2021.105557
   PubMed Web of Science ®Google Scholar
• Chaaban I, Rizk OH, Ibrahim TM, et al. Synthesis, anti-inflammatory screening, molecular docking, and COX-1,2/-5-LOX inhibition profile of some novel quinoline derivatives. Bioorg. Chem. 2018;78:220–235. doi:10.1016/j.bioorg.2018.03.023
   PubMed Web of Science ®Google Scholar
• Nikookar H, Mohammadi-Khanaposhtani M, Imanparast S, et al. Design, synthesis and in vitro α-glucosidase inhibition of novel dihydropyrano[3,2-c]quinoline derivatives as potential anti-diabetic agents. Bioorg. Chem. 2018;77:280–286. doi:10.1016/j.bioorg.2018.01.025
   PubMed Web of Science ®Google Scholar
• Ganesan M, Raja KK, Narasimhan K, et al. Design, synthesis, α-amylase inhibition and in silico docking study of novel quinoline bearing proline derivatives. J. Mol. Struct. 2020;1208:127873–127881. doi:10.1016/j.molstruc.2020.127873
   Web of Science ®Google Scholar
• Aly RM, Serya RA, El-Motwally AM, et al. Novel quinoline-3-carboxamides (Part 2): Design, optimization and synthesis of quinoline based scaffold as EGFR inhibitors with potent anticancer activity. Bioorg. Chem. 2017;75:368–392. doi:10.1016/j.bioorg.2017.10.018
   PubMed Web of Science ®Google Scholar
• Batran RZ, El-Daly SM, El-Kashak WA, et al. Design, synthesis, and molecular modeling of quinoline-based derivatives as anti-breast cancer agents targeting EGFR/AKT signaling pathway. Chem. Biol. Drug Design. 2022;99:470–482. doi:10.1111/cbdd.14012
   PubMed Web of Science ®Google Scholar
• Kardile RA, Sarkate AP, Lokwani DK, et al. Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: in vitro screening and ADME predictions. Eur. J. Med. Chem. 2023;245:114889–114899. doi:10.1016/j.ejmech.2022.114889
   PubMed Web of Science ®Google Scholar
• Nicolaï E, Güngör T, Goyard J, et al. Synthesis and aldose reductase inhibitory activity of N-(quinolinyl thiocarbonyl) glycine derivatives. Eur. J. Med. Chem. 1992;27:977–984. doi:10.1016/0223-5234(92)90032-V
   Web of Science ®Google Scholar
• Huang L, Yang L, Wan J-P, et al. Metal-free three-component assemblies of anilines, α-keto acids and alkyl lactates for quinoline synthesis and their anti-inflammatory activity. Org. Biomol. Chem. 2022;20:4385–4390. doi:10.1039/d2ob00661h
   PubMed Web of Science ®Google Scholar
• Hamdy R, Elseginy SA, Ziedan NI, et al. New quinoline-based heterocycles as anticancer agents targeting Bcl-2. Molecules. 2019;24:1274–1283. doi:10.3390/molecules24071274
   PubMed Web of Science ®Google Scholar
• Baba-Ahmed I, Kibou Z, Daoud I, et al. Synthesis, molecular docking and ADME-TOX studies of new tacrine analogs as promising for Alzheimer's disease therapy. Curr. Org. Chem. 2022;26:1218–1233. doi:10.2174/1385272826666220914114544
   Web of Science ®Google Scholar
• Tokalı FS, Taslimi P, Demircioğlu İH, et al. Novel phenolic Mannich base derivatives: synthesis, bioactivity, molecular docking, and ADME-Tox Studies. J. Iran Chem. Soc. 2022;19:563–577. doi:10.1007/s13738-021-02331-8
   Web of Science ®Google Scholar
• Mellado M, González C, Mella J, et al. Combined 3D-QSAR and docking analysis for the design and synthesis of chalcones as potent and selective monoamine oxidase B inhibitors. Bioorg. Chem. 2021;108:104689. doi:10.1016/j.bioorg.2021.104689
   PubMed Web of Science ®Google Scholar
• Tilekar K, Upadhyay N, Meyer-Almes F-J, et al. Synthesis and biological evaluation of pyrazoline and pyrrolidine-2,5-dione hybrids as potential antitumor agents. ChemMedChem. 2020;15:1813–1825. doi:10.1002/cmdc.202000458
   PubMed Web of Science ®Google Scholar
• Liu F, Yang J-F, Liu H, et al. Facile microwave-assisted synthesis of 1,3,5-trisubstituted pyrazoline derivatives incorporating sulfonyl moiety. J. Chin. Chem. Soc. 2016;63:254–260. doi:10.1002/jccs.201500385
   Web of Science ®Google Scholar
• Inc C. Molecular Operating Environment (MOE). Montreal, QC, Canada: Chemical Computing Group Inc.; 2016.
   Google Scholar
• Elmaaty AA, Alnajjar R, Hamed MI, et al. Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study. RSC Adv. 2021;11:10027–10042. doi:10.1039/D0RA10674G
   PubMed Web of Science ®Google Scholar
• Elmaaty AA, Darwish KM, Khattab M, et al. In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins. J. Biomol. Struct. Dyn. 2022;40:8866–8893. doi:10.1080/07391102.2021.1918256
   PubMed Web of Science ®Google Scholar
• Abo Elmaaty A, Hamed MIA, Ismail MI, et al. Computational insights on the potential of some NSAIDs for treating COVID-19: priority set and lead optimization. Molecules. 2021;26:3772–3783. doi:10.3390/molecules26123772
   PubMed Web of Science ®Google Scholar
• Hamed MI, Darwish KM, Soltane R, et al. β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization. RSC Adv. 2021;11:35536–35558. doi:10.1039/D1RA04820A
   PubMed Web of Science ®Google Scholar
• Elmaaty AA, Darwish KM, Chrouda A, et al. In silico and in vitro studies for benzimidazole anthelmintics repurposing as VEGFR-2 antagonists: novel mebendazole-loaded mixed micelles with enhanced dissolution and anticancer activity. ACS Omega. 2022;7:875–899. doi:10.1021/acsomega.1c05519
   PubMed Web of Science ®Google Scholar
• Elebeedy D, Badawy I, Elmaaty AA, et al. In vitro and computational insights revealing the potential inhibitory effect of Tanshinone IIA against influenza A virus. Comput. Biol. Med. 2022;141:105149–105160. doi:10.1016/j.compbiomed.2021.105149
   PubMed Web of Science ®Google Scholar
• Hammoud MM, Nageeb AS, Morsi MA, et al. Design, synthesis, biological evaluation, and SAR studies of novel cyclopentaquinoline derivatives as DNA intercalators, topoisomerase II inhibitors, and apoptotic inducers. New. J. Chem. 2022;46:11422–11436. doi:10.1039/d2nj01646j
   Web of Science ®Google Scholar
• Hammouda MM, Elmaaty AA, Nafie MS, et al. Design and synthesis of novel benzoazoninone derivatives as potential CBSIs and apoptotic inducers: In Vitro, in Vivo, molecular docking, molecular dynamics, and SAR studies. Bioorg. Chem. 2022;127:105995–1051003. doi:10.1016/j.bioorg.2022.105995
   PubMed Web of Science ®Google Scholar
• Saleh MA, Elmaaty AA, El Saeed HS, et al. Structure based design and synthesis of 3-(7-nitro-3-oxo-3,4-dihydroquinoxalin-2-yl)propanehydrazide derivatives as novel bacterial DNA-gyrase inhibitors: in-vitro, in-vivo, in-silico and SAR studies. Bioorg. Chem. 2022;129:106186. doi:10.1016/j.bioorg.2022.106186
   PubMed Web of Science ®Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002;277:46265–46272. doi:10.1074/jbc.M207135200
   PubMed Web of Science ®Google Scholar
• El-Shershaby MH, El-Gamal KM, Bayoumi AH, et al. The antimicrobial potential and pharmacokinetic profiles of novel quinoline-based scaffolds: synthesis and in silico mechanistic studies as dual DNA gyrase and DHFR inhibitors. New. J. Chem. 2021;45:13986–14004. doi:10.1039/d1nj02838c
   Web of Science ®Google Scholar
• Hazem RM, Antar SA, Nafea YK, et al. Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor. Life Sci. 2022;288:120185–120194. doi:10.1016/j.lfs.2021.120185
   PubMed Web of Science ®Google Scholar
• Kandeil A, Mostafa A, Kutkat O, et al. Bioactive polyphenolic compounds showing strong antiviral activities against severe acute respiratory syndrome coronavirus 2. Pathogens. 2021;10:758–789. doi:10.3390/pathogens10060758
   PubMed Web of Science ®Google Scholar
• Mahmoud DB, Bakr MM, Al-karmalawy AA, et al. Scrutinizing the feasibility of nonionic surfactants to form isotropic bicelles of curcumin: a potential antiviral candidate against COVID-19. AAPS PharmSciTech. 2021;23:44–62. doi:10.1208/s12249-021-02197-2
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017;7:42717–42727. doi:10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Pires DEV, Blundell TL, Ascher DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 2015;58:4066–4072. doi:10.1021/acs.jmedchem.5b00104
   PubMed Web of Science ®Google Scholar
• Ahn JW, Song YJ, Park K. In vitro anti-cancer effects of gefitinib via EGF receptor-targeted delivery on triple-negative breast cancer cells. Macromol. Res. 2023;31:837–842. doi:10.1007/s13233-023-00178-x
   Web of Science ®Google Scholar
• Kumar A, Kumar B, Bhatia R. Design, synthesis, molecular docking, and biological evaluation of Isatin-based fused heterocycles as epidermal growth factor receptor inhibitors. Assay Drug Dev. Technol. 2023;21:222–233. doi:10.1089/adt.2022.120
   PubMed Web of Science ®Google Scholar
• Chen F, Liu J, Flight RM, et al. Cellular origins of EGFR-driven lung cancer cells determine sensitivity to therapy. Adv. Sci. 2021;8:2101999–2102010. doi:10.1002/advs.202101999
   Web of Science ®Google Scholar
• Fayad E, Altalhi SA, Abualnaja MM, et al. Novel acrylate-based derivatives: design, synthesis, antiproliferative screening, and docking study as potential combretastatin analogues. ACS Omega. 2023;8:38394–38405. doi:10.1021/acsomega.3c05051
   PubMedGoogle Scholar
• El-Lateef HMA, Saleem RM, Bazuhair MA, et al. Design, synthesis and tubulin polymerization inhibition activity of newly synthesized hydrazone-linked to combretastatin analogues as potential anticancer agents. J. Mol. Struct. 2023;1292:136190. doi:10.1016/j.molstruc.2023.136190
   Web of Science ®Google Scholar
• El-Demerdash A, Al-Karmalawy AA, Abdel-Aziz TM, et al. Investigating the structure-activity relationship of marine natural polyketides as promising SARS-CoV-2 main protease inhibitors. RSC Adv. 2021;11:31339–31363. doi:10.1039/D1RA05817G
   PubMed Web of Science ®Google Scholar
• Elebeedy D, Elkhatib WF, Kandeil A, et al. Anti-SARS-CoV-2 activities of tanshinone IIA, carnosic acid, rosmarinic acid, salvianolic acid, baicalein, and glycyrrhetinic acid between computational and in vitro insights. RSC Adv. 2021;11:29267–29286. doi:10.1039/D1RA05268C
   PubMed Web of Science ®Google Scholar
• Khattab M, Al-Karmalawy AA. Computational repurposing of benzimidazole anthelmintic drugs as potential colchicine binding site inhibitors. Future Med. Chem. 2021;13:1623–1638. doi:10.4155/fmc-2020-0273
   PubMed Web of Science ®Google Scholar
• Scalbert A, Morand C, Manach C, et al. Absorption and metabolism of polyphenols in the gut and impact on health. Biomed. Pharmacother. 2002;56:276–282. doi:10.1016/S0753-3322(02)00205-6
   PubMed Web of Science ®Google Scholar
• Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Delivery Rev. 2001;52:117–126. doi:10.1016/S0169-409X(01)00231-9
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997;23:3–25. doi:10.1016/S0169-409X(96)00423-1
   Web of Science ®Google Scholar
• Levy DD, Zeiger E, Escobar PA, et al. Recommended criteria for the evaluation of bacterial mutagenicity data (Ames test). Mutat. Research/Genet. Toxicol. Environ. Mutagen. 2019;848:403074–403083. doi:10.1016/j.mrgentox.2019.07.004
   PubMed Web of Science ®Google Scholar
• Roy S, Mathew M. Fluid flow modulates electrical activity in cardiac hERG potassium channels. J. Biol. Chem. 2018;293:4289–4303. doi:10.1074/jbc.RA117.000432
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC. HERG1 channel agonists and cardiac arrhythmia. Curr. Opin. Pharmacol. 2014;15:22–27. doi:10.1016/j.coph.2013.11.006
   PubMed Web of Science ®Google Scholar